Actively Recruiting
Study Comparing Hypofractionated and Conventional Radiotherapy After Surgery for Thymic Epithelial Tumors
Led by Rongrong Zhou · Updated on 2024-11-18
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating whether hypofractionated radiotherapy can shorten treatment time without increasing side effects for patients with thymic epithelial tumors, including thymoma and thymic carcinoma. This study compares the effectiveness and safety of hypofractionated radiotherapy with conventional radiotherapy after surgery to treat these tumors. Participants will receive either hypofractionated or conventional radiotherapy following surgery. Hypofractionated radiotherapy delivers higher doses in fewer sessions, aiming to reduce overall treatment duration. The radiation doses vary based on the extent of tumor removal R0, R1, or R2 resection, with different dose schedules for each group. The study does not use randomization, and patients choose their treatment group. During the study, participants will visit the hospital every 12 weeks for checkups and tests over a follow-up period of three years. Researchers will monitor disease progression, survival rates, and treatment toxicity. The main outcome measured is the three-year progression-free survival, with additional monitoring for overall survival and side effects to assess safety over the same period.
CONDITIONS
Brief Title
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
Research Team
R
Rongrong Zhou, MD, PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
